Treatment Focused Genetic Testing (Tfgt) For Ovarian Cancer (Oc) Patients: The Catalan Institute Of Oncology (Ico) Network Experience.

e17071 Background: Since the approval of the PARP inhibitor olaparib, the TFGT indications for OC have dramatically increased. Furthermore, several guidelines include genetic testing for all non-mucinous OC patients irrespectively of age and family history. Methods: The ICO network comprises 4 Medical Oncology Departments, 3 Cancer Genetic Counselling Units (CGCU) and 2 Cancer Family Units (CFU) being all of them referral centres for a total of 25 hospitals that cover a population of 3.5 m inhabitants. In December 2014, the Gyne Oncologists Team in collaboration with the CGCU members and the Molecular Diagnosis Laboratory (MDL) of the ICO network established a consensus protocol on indications for risk assessment (RA) and TFGT. All new pts diagnosed with epithelial non-mucinous OC or platinum sensitive relapse were referred to CGCU. An express track for RA at CGCU (0-10 days) and test results delivery ( < 35 days) was defined for OC patients whose germline BRCA1/2 test results were needed to tailor their treatment. Results: Between January 1st and November 30th, 115 new OC patients were refered to the CGCU. 27 (23 %) followed the express track. Median time from the referral date to test results for standard GC was 77 days (36-98) and 27 days (18-65) for express GC. Median age was 59 (23-80) and 63% had not family history of cancer. Serous carcinoma was the most frequent histology (96 %). BRCA1/2 results were available for 100 patients. Deleterious mutations were identified in 22% of patients (15% in the group without family history of cancer). Variants of uncertain significance were found in 9% of cases. Conclusions: After an initial 11 months experience review, our protocol warrants adequate RA for all patients tested for BRCA1/2 mutations as well as quick results when needed to establish a therapeutic strategy. Time to first appointment for RA and test results was optimal for patients with olaparib indication. The relatively high frequency of germline BRCA1/2 mutations could be explained by the bias selection of patients with platinum sensitive relapse. We continue to implement the protocol to end up testing all patients at diagnosis after having the results for all prevalent cases.